نتائج البحث - Nick Thatcher

  • يعرض 1 - 14 نتائج من 14
تنقيح النتائج
  1. 1
    ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer

    ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer حسب Richard Booton, Tim Ward, Linda Ashcroft, Julie Morris, Jim Heighway, Nick Thatcher

    منشور في 2007
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer

    Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer حسب Paul Lorigan, Penella J. Woll, Mary O’Brien, Linda Ashcroft, M Sampson, Nick Thatcher

    منشور في 2005
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Epidermal growth factor receptor immunohistochemistry

    Epidermal growth factor receptor immunohistochemistry حسب Fred R. Hirsch, Rafał Dziadziuszko, Nick Thatcher, Helen Mann, Claire Watkins, Dinah V. Parums, Georgina Speake, Brian R. Holloway, Paul A. Bunn, Wilbur A. Franklin

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

    Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study حسب Alex Y. Chang, Purvish M. Parikh, Sumitra Thongprasert, Eng Huat Tan, Reury-Perng Perng, Domingo Ganzon, James Chih‐Hsin Yang, Chao‐Jung Tsao, Claire Watkins, N. Botwood, Nick Thatcher

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Second-Line Treatment of Advanced Non-small Cell Lung Cancer

    Second-Line Treatment of Advanced Non-small Cell Lung Cancer حسب Cesare Gridelli, Andrea Ardizzoni, Fortunato Ciardiello, Nasser H. Hanna, John V. Heymach, Francesco Perrone, Rafael Rosell, Frances A. Shepherd, Nick Thatcher, Johan Vansteenkiste, Luigi De Petris, Massimo Di Maïo, Filippo de Marinis

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012

    Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012 حسب Fred R. Hirsch, Pasi A. Jänne, Wilfried Eberhardt, Federico Cappuzzo, Nick Thatcher, Robert Pirker, Hak Choy, Edward S. Kim, Luis Paz‐Ares, David R. Gandara, Yi‐Long Wu, Myung‐Ju Ahn, Tetsuya Mitsudomi, Frances A. Shepherd, Tony Mok

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer

    Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer حسب Mark A. Socinski, Egbert F. Smit, Paul Lorigan, Kartik Konduri, Martin Reck, Aleksandra Szczęsna, Johnetta Blakely, Piotr Serwatowski, Nina Karaseva, Tudor‐Eliade Ciuleanu, Jacek Jassem, Mircea Dediu, Shengyan Hong, Carla Visseren‐Grul, Axel-Rainer Hanauske, Coleman K. Obasaju, Susan C. Guba, Nick Thatcher

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an o... حسب Nick Thatcher, Fred R. Hirsch, Alexander Luft, Aleksandra Szczęsna, Tudor‐Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, H. Depenbrock, Shivani Nanda, Anamarija Kruljac‐Letunic, Raffael Kurek, Luis Paz‐Ares, Mark A. Socinski

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

    Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer حسب Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather A. Wakelee, Nick Thatcher

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

    Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment حسب Corey J. Langer, Coleman K. Obasaju, Paul A. Bunn, Philip Bonomi, David R. Gandara, Fred R. Hirsch, Edward S. Kim, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, Mark A. Socinski, David R. Spigel, Heather A. Wakelee, Carlos Mayo, Nick Thatcher

    منشور في 2016
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

    Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer حسب Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn, Wilbur A. Franklin, Rafał Dziadziuszko, Nick Thatcher, Alex Y. Chang, Purvish M. Parikh, José Rodrigues Pereira, Tudor‐Eliade Ciuleanu, Joachim von Pawel, Claire Watkins, Angela V. Flannery, Gillian Ellison, Emma Donald, Lucy Knight, Dinah V. Parums, Nicholas Botwood, Brian R. Holloway

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial حسب Charles Butts, Mark A. Socinski, Paul Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor‐Eliade Ciuleanu, Lionel Bosquée, José Trigo, Alexander I. Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, José Rodrigues Pereira, Wilfried Eberhardt, Christoph Helwig, Andreas Schröder, Frances A. Shepherd

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Clinicopathologic Features of Advanced Squamous NSCLC

    Clinicopathologic Features of Advanced Squamous NSCLC حسب Mark A. Socinski, Coleman K. Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz‐Ares, M. Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Thomas E. Stinchcombe, Heather A. Wakelee, Carlos Mayo, Nick Thatcher

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

    Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled p... حسب Luis Paz‐Ares, J. Mezger, Tudor‐Eliade Ciuleanu, Jürgen R. Fischer, Joachim von Pawel, Mariano Provencio, Andrzej Każarnowicz, György Losonczy, Gilberto de Castro, Aleksandra Szczęsna, Lucio Crinò, Martin Reck, Rodryg Ramlau, Ernst Ulsperger, Christian Schumann, José Elias Miziara, Álvaro Edson Ramos Lessa, Mircea Dediu, Beatrix Bálint, H. Depenbrock, Victoria Soldatenkova, Raffael Kurek, Fred R. Hirsch, Nick Thatcher, Mark A. Socinski

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: